Whole-body PET/MRI to detect bone metastases: comparison of the diagnostic performance of the sequences

1. Yu H, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control 2012; 19: 84–91. doi: 10.1177/107327481201900202 YuH TsaiYY HoffeSE Overview of diagnosis and management of metastatic disease to bone Cancer Control 2012 19 84 91 10.1177/107327481201900202 Open DOISearch in Google Scholar

2. Baüerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol 2009; 19: 2495–507. doi: 10.1007/s00330-009-1443-1 BaüerleT SemmlerW Imaging response to systemic therapy for bone metastases Eur Radiol 2009 19 2495 507 10.1007/s00330-009-1443-1 Open DOISearch in Google Scholar

3. Vassiliou V, Andreopoulos D, Frangos S, Tselis N, Giannopoulou E, Lutz S. Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol 2011; 23: 632–45. doi: 10.1016/j.clon.2011.03.010 VassiliouV AndreopoulosD FrangosS TselisN GiannopoulouE LutzS Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities Clin Oncol 2011 23 632 45 10.1016/j.clon.2011.03.010 Open DOISearch in Google Scholar

4. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol 2015; 7: 202. doi: 10.4329/wjr.v7.i8.202 O’SullivanGJ CartyFL CroninCG Imaging of bone metastasis: an update World J Radiol 2015 7 202 10.4329/wjr.v7.i8.202 Open DOISearch in Google Scholar

5. Even-Sapir E, Metser U, Mishani E. The detection of bone metastases in patients with high-risk prostate cancer: ^99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, ¹⁸F-fluoride PET, and ¹⁸F-fluoride PET/CT. J Nucl Med 2006; 47: 287–97. PMID: 16455635 Even-SapirE MetserU MishaniE The detection of bone metastases in patients with high-risk prostate cancer: ^99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, ¹⁸F-fluoride PET, and ¹⁸F-fluoride PET/CT J Nucl Med 2006 47 287 97 16455635 Search in Google Scholar

6. Römer W, Nömayr A, Uder M, Werner Bautz, Torsten Kuwert. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006; 47: 1102–6. PMID: 16818944 RömerW NömayrA UderM BautzWerner KuwertTorsten SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients J Nucl Med 2006 47 1102 6 16818944 Search in Google Scholar

7. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2006; 238: 264–71. doi: 10.1148/radiol.2373041358 UtsunomiyaD ShiraishiS ImutaM TomiguchiS KawanakaK MorishitaS Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT Radiology 2006 238 264 71 10.1148/radiol.2373041358 Open DOISearch in Google Scholar

8. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007; 17: 939–49. doi: 10.1007/s00330-006-0361-8 SchmidtGP SchoenbergSO SchmidR StahlR TilingR BeckerCR Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT Eur Radiol 2007 17 939 49 10.1007/s00330-006-0361-8 Open DOISearch in Google Scholar

9. Kogan F, Broski SM, Yoon D, Gold GE. Applications of PET-MRI in musculoskeletal disease. J Magn Reson Imaging 2018; 48: 27–47. doi:10.1002/jmri.26183 KoganF BroskiSM YoonD GoldGE Applications of PET-MRI in musculoskeletal disease J Magn Reson Imaging 2018 48 27 47 10.1002/jmri.26183 Open DOISearch in Google Scholar

10. Vanel D, Dromain C, Tardivon A. MRI of bone marrow disorders. Eur Radiol 2000; 10: 224–229. doi: 10.1007/s003300050038 VanelD DromainC TardivonA MRI of bone marrow disorders Eur Radiol 2000 10 224 229 10.1007/s003300050038 Open DOISearch in Google Scholar

11. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion weighted MR imaging in cancer: current status and research directions. Radiology 2011; 261: 700–18. doi: 10.1148/radiol.11110474 PadhaniAR KohDM CollinsDJ Whole-body diffusion weighted MR imaging in cancer: current status and research directions Radiology 2011 261 700 18 10.1148/radiol.11110474 Open DOISearch in Google Scholar

12. Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, et al. [181F] fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy. J Clin Oncol 2016; 34: 1889–97. doi: 10.1200/JCO.2015.63.5185 HildebrandtMG GerkeO BaunC FalchK HansenJA FarahaniZA [181F] fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy J Clin Oncol 2016 34 1889 97 10.1200/JCO.2015.63.5185 Open DOISearch in Google Scholar

13. Park S, Yoon J-K, Lee SJ, Kang SY, Yim H, An Y-S. Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis. Medicine 2017; 96: e8985. doi: 10.1097/MD.0000000000008985 ParkS YoonJ-K LeeSJ KangSY YimH AnY-S Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis Medicine 2017 96 e8985 10.1097/MD.0000000000008985 Open DOISearch in Google Scholar

14. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [¹⁸F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25: 3440–7. doi: 10.1200/JCO.2007.11.2854 DuY CullumI IllidgeTM EllPJ Fusion of metabolic function and morphology: sequential [¹⁸F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer J Clin Oncol 2007 25 3440 7 10.1200/JCO.2007.11.2854 Open DOISearch in Google Scholar

15. Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: ^99mTc-MDP planar bone scintigraphy, ¹⁸F-fluoride PET or ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 1807. doi: 10.1007/s00259-009-1181-2 KrügerS BuckAK MottaghyFM HasenkampE PaulsS SchumannC Detection of bone metastases in patients with lung cancer: ^99mTc-MDP planar bone scintigraphy, ¹⁸F-fluoride PET or ¹⁸F-FDG PET/CT Eur J Nucl Med Mol Imaging 2009 36 1807 10.1007/s00259-009-1181-2 Open DOISearch in Google Scholar

16. Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 2011; 52: 1009–14. doi: 10.1258/ar.2011.100507 HahnS HeusnerT KümmelS KöningerA NagarajahJ MüllerS Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer Acta Radiol 2011 52 1009 14 10.1258/ar.2011.100507 Open DOISearch in Google Scholar

17. Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21: 2604–17. doi: 10.1007/s00330-011-2221-4 YangHL LiuT WangXM XuY DengSM Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy Eur Radiol 2011 21 2604 17 10.1007/s00330-011-2221-4 Open DOISearch in Google Scholar

18. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009; 34: 417–20. doi: 10.1097/RLU.0b013e3181a7d03c HuygeV GarciaC VanderstappenA AlexiouJ GilT FlamenP Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET Clin Nucl Med 2009 34 417 20 10.1097/RLU.0b013e3181a7d03c Open DOISearch in Google Scholar

19. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1253–8. doi: 10.1007/s00259-005-1842-8 NakaiT OkuyamaC KubotaT YamadaK UshijimaY TaniikeK Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer Eur J Nucl Med Mol Imaging 2005 32 1253 8 10.1007/s00259-005-1842-8 Open DOISearch in Google Scholar

20. Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A metanalysis of ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 2011; 40: 523–31. doi: 10.1007/s00256-010-0963-8 LiuT ChengT XuW YanWL LiuJ YangHL A metanalysis of ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer Skeletal Radiol 2011 40 523 31 10.1007/s00256-010-0963-8 Open DOISearch in Google Scholar

21. Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, ¹⁸F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 2016; 55: 59–67. doi: 10.3109/0284186X.2015.1027411 JamborI KuismaA RamadanS HuovinenR SandellM KajanderS Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, ¹⁸F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial Acta Oncol 2016 55 59 67 10.3109/0284186X.2015.1027411 Open DOISearch in Google Scholar

22. Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005; 55: 41–55. doi: 10.1016/j.ejrad.2005.01.016 GhanemN UhlM BrinkI SchäferO KellyT MoserE Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone Eur J Radiol 2005 55 41 55 10.1016/j.ejrad.2005.01.016 Open DOISearch in Google Scholar

23. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of ¹⁸FDG-PET–CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012; 81: 1007–15. doi: 10.1016/j.ejrad.2011.01.126 QuX HuangX YanW WuL DaiK A meta-analysis of ¹⁸FDG-PET–CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer Eur J Radiol 2012 81 1007 15 10.1016/j.ejrad.2011.01.126 Open DOISearch in Google Scholar

24. Eiber M, Takei T, Souvatzoglou M, Fürst S, Gaertner FC, Loeffelbein DJ, et al. Performance of whole-body integrated ¹⁸F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med 2014; 55: 191–7. doi: 10.2967/jnumed.113.123646 EiberM TakeiT SouvatzoglouM FürstS GaertnerFC LoeffelbeinDJ Performance of whole-body integrated ¹⁸F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions J Nucl Med 2014 55 191 7 10.2967/jnumed.113.123646 Open DOISearch in Google Scholar

25. Beiderwellen K, Huebner M, Heusch P, Grueneisen J, Ruhlmann V, Nensa F, et al. Whole-body [(1)(8)F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol 2014; 24: 2023–30. doi: 10.1007/s00330-014-3229-3 BeiderwellenK HuebnerM HeuschP GrueneisenJ RuhlmannV NensaF Whole-body [(1)(8)F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results Eur Radiol 2014 24 2023 30 10.1007/s00330-014-3229-3 Open DOISearch in Google Scholar

26. Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, et al. A prospective study comparing ^99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with ¹⁸F-fluoride PET/CT and ¹⁸F-fluoride PET/MRI for diagnosing bone metastases. J Nucl Med 2017; 58: 1778–85. doi: 10.2967/jnumed.116.189183 LöfgrenJ MortensenJ RasmussenSH MadsenC LoftA HansenAE A prospective study comparing ^99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with ¹⁸F-fluoride PET/CT and ¹⁸F-fluoride PET/MRI for diagnosing bone metastases J Nucl Med 2017 58 1778 85 10.2967/jnumed.116.189183 Open DOISearch in Google Scholar

27. Bruckmann NM, Kirchner IJ, Umutlu L, Fendler WF, Seifert R, Hermann K, et al. Prospective comparison of the diagnostic accuracy of ¹⁸F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 2021; 31: 8714–24. doi: 10.1007/s00330-021-07956-0 BruckmannNM KirchnerIJ UmutluL FendlerWF SeifertR HermannK Prospective comparison of the diagnostic accuracy of ¹⁸F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients Eur Radiol 2021 31 8714 24 10.1007/s00330-021-07956-0 Open DOISearch in Google Scholar

28. Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, et al. Comparison of CE FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer 2015; 112: 1452–60. doi: 10.1038/bjc.2015.112 CatalanoOA NicolaiE RosenBR LuongoA CatalanoM IannaceC Comparison of CE FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients Br J Cancer 2015 112 1452 60 10.1038/bjc.2015.112 Open DOISearch in Google Scholar

29. Sonni I, Minamimoto R, Baratto L, Gambhir SS, Loening AM, Vasanawala SS, et al. Simultaneous PET/MRI in the evaluation of breast and prostate cancer using combined Na[¹⁸F] F and [¹⁸F]FDG: a focus on skeletal lesions. Mol Imaging Biol 2020; 22: 397–406. doi: 10.1007/s11307-020-01471-2 SonniI MinamimotoR BarattoL GambhirSS LoeningAM VasanawalaSS Simultaneous PET/MRI in the evaluation of breast and prostate cancer using combined Na[¹⁸F] F and [¹⁸F]FDG: a focus on skeletal lesions Mol Imaging Biol 2020 22 397 406 10.1007/s11307-020-01471-2 Open DOISearch in Google Scholar

30. Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, et al. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol 2016; 85: 459–65. doi: 10.1016/j.ejrad.2015.12.010 SawickiLM GrueneisenJ SchaarschmidtBM BuchbenderC NagarajahJ UmutluL Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer Eur J Radiol 2016 85 459 65 10.1016/j.ejrad.2015.12.010 Open DOISearch in Google Scholar

31. Samarin A, Hullner M, Queiroz MA, Stolzmann P, Burger IA, Schulthess G, et al. ¹⁸F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with ¹⁸F-FDG-PET/CT. Nucl Med Commun 2015; 36: 1165–1173. doi: 10.1097/MNM.0000000000000387 SamarinA HullnerM QueirozMA StolzmannP BurgerIA SchulthessG ¹⁸F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with ¹⁸F-FDG-PET/CT Nucl Med Commun 2015 36 1165 1173 10.1097/MNM.0000000000000387 Open DOISearch in Google Scholar

32. Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid ⁶⁸Ga-PSMA PET/MRI and ⁶⁸Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 70–83. doi: 10.1007/s00259-015-3206-3 FreitagMT RadtkeJP HadaschikBA Kopp-SchneiderA EderM KopkaK Comparison of hybrid ⁶⁸Ga-PSMA PET/MRI and ⁶⁸Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer Eur J Nucl Med Mol Imaging 2016 43 70 83 10.1007/s00259-015-3206-3 Open DOISearch in Google Scholar

33. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser M. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999; 23: 123–9. doi: 10.1097/00004728-199901000-00026 SteinbornMM HeuckAF TilingR BruegelM GaugerL ReiserM Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system J Comput Assist Tomogr 1999 23 123 9 10.1097/00004728-199901000-00026 Open DOISearch in Google Scholar

34. Zhan Y, Zhang G, Li M, Zhou X. Whole-body MRI vs. PET/CT for the detection of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Front Oncol 2021; 11: 633833. doi: 10.3389/fonc.2021.633833 ZhanY ZhangG LiM ZhouX Whole-body MRI vs. PET/CT for the detection of bone metastases in patients with prostate cancer: a systematic review and meta-analysis Front Oncol 2021 11 633833 10.3389/fonc.2021.633833 Open DOISearch in Google Scholar

35. Bashir U, Mallia A, Stirling J, Joemon J, MacKewn J, Charles-Edwards G, et al. PET/MRI in oncological imaging: state of the art. Diagnostics 2015; 5: 333–57. doi: 10.3390/diagnostics5030333 BashirU MalliaA StirlingJ JoemonJ MacKewnJ Charles-EdwardsG PET/MRI in oncological imaging: state of the art Diagnostics 2015 5 333 57 10.3390/diagnostics5030333 Open DOISearch in Google Scholar

36. Araz M, Aras G, Kucuk ON. The role of ¹⁸F-NaF PET/CT in metastatic bone disease. J Bone Oncol 2015; 16: 92–7. doi: 10.1016/j.jbo.2015.08.002 ArazM ArasG KucukON The role of ¹⁸F-NaF PET/CT in metastatic bone disease J Bone Oncol 2015 16 92 7 10.1016/j.jbo.2015.08.002 Open DOISearch in Google Scholar